Literature DB >> 7047482

Investigation of the beta-lactamase stability of ceftazidime and eight other new cephalosporin antibiotics.

I N Simpson, S J Plested, P B Harper.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7047482     DOI: 10.1093/jac/9.5.357

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  7 in total

1.  In vitro investigation of BK-218, a new oral and parenteral cephalosporin.

Authors:  I Szabó; J Barabás; A Tar; L Kiss; M Filep; T Schmidt; K Marossy; B Tóth-Martinez; G Barabás; F Hernádi
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

2.  Paradoxical antibacterial activities of beta-lactams against Proteus vulgaris: mechanism of the paradoxical effect.

Authors:  Y Ikeda; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

3.  Paradoxical antibacterial activity of cefmenoxime against Proteus vulgaris.

Authors:  Y Ikeda; T Nishino; T Tanino
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

Review 4.  Cefmenoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

5.  beta-Lactamase-mediated inactivation and efficacy of cefazolin and cefmetazole in Staphylococcus aureus abscesses.

Authors:  M T Fields; B L Herndon; D M Bamberger
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

Review 6.  Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R C Heel
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

Review 7.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.